{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:51:02Z","timestamp":1789523462161,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM007739"],"award-info":[{"award-number":["T32GM007739"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hyperactivation of the cystic fibrosis transmembrane conductance regulator (CFTR) contributes to secretory diarrhea, a major cause of pediatric mortality worldwide, and autosomal dominant polycystic kidney disease (ADPKD), the most common inherited cause of end-stage renal disease. Selective CFTR inhibition is a potential therapeutic strategy, with (<jats:italic>R<\/jats:italic>)-BPO-27 emerging as a promising candidate. Here, we present a cryo-EM structure of CFTR bound to (<jats:italic>R<\/jats:italic>)-BPO-27 at an overall resolution of 2.1\u2009\u00c5. Contrary to the previous hypothesis that it inhibits CFTR current by competition with ATP, we demonstrate that (<jats:italic>R<\/jats:italic>)-BPO-27 instead directly occludes the chloride-conducting pore while permitting ATP hydrolysis, thus uncoupling the two activities. Furthermore, we find that inhibitor binding requires some degree of NBD separation, as the inhibition rate inversely correlates with the probability NBD dimerization. These findings clarify the compound\u2019s mechanism and provide a molecular basis for optimizing its clinical potential.<\/jats:p>","DOI":"10.1038\/s41467-025-62199-7","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T12:19:34Z","timestamp":1754050774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Structure of CFTR bound to (R)-BPO-27 unveils a pore-blockage mechanism"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-5259","authenticated-orcid":false,"given":"Paul G.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Fiedorczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-4283","authenticated-orcid":false,"given":"Jue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"62199_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","volume":"74","author":"V Saint-Criq","year":"2017","unstructured":"Saint-Criq, V. & Gray, M. A. Role of CFTR in epithelial physiology. Cell. Mol. Life Sci. 74, 93\u2013115 (2017).","journal-title":"Cell. Mol. Life Sci."},{"key":"62199_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/0092-8674(91)90446-6","volume":"66","author":"SH Cheng","year":"1991","unstructured":"Cheng, S. H. et al. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 66, 1027\u20131036 (1991).","journal-title":"Cell"},{"key":"62199_CR3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409049121","volume":"121","author":"K Fiedorczuk","year":"2024","unstructured":"Fiedorczuk, K. et al. The structures of protein kinase A in complex with CFTR: mechanisms of phosphorylation and noncatalytic activation. Proc. Natl. Acad. Sci. USA 121, e2409049121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62199_CR4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2407728121","volume":"121","author":"C Mih\u00e1lyi","year":"2024","unstructured":"Mih\u00e1lyi, C., Iordanov, I., Szollosi, A. & Csan\u00e1dy, L. Structural determinants of protein kinase A essential for CFTR channel activation. Proc. Natl. Acad. Sci. USA 121, e2407728121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62199_CR5","doi-asserted-by":"publisher","first-page":"26626","DOI":"10.1074\/jbc.270.44.26626","volume":"270","author":"PJ French","year":"1995","unstructured":"French, P. J. et al. Isotype-specific activation of cystic fibrosis transmembrane conductance regulator-chloride channels by cGMP-dependent protein kinase II. J. Biol. Chem. 270, 26626\u201326631 (1995).","journal-title":"J. Biol. Chem."},{"key":"62199_CR6","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1074\/jbc.272.7.4195","volume":"272","author":"AB Vaandrager","year":"1997","unstructured":"Vaandrager, A. B. et al. cGMP stimulation of cystic fibrosis transmembrane conductance regulator Cl\u2212 channels co-expressed with cGMP-dependent protein kinase type II but not type I\u03b2*. J. Biol. Chem. 272, 4195\u20134200 (1997).","journal-title":"J. Biol. Chem."},{"key":"62199_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrg3849","volume":"16","author":"GR Cutting","year":"2015","unstructured":"Cutting, G. R. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat. Rev. Genet. 16, 45\u201356 (2015).","journal-title":"Nat. Rev. Genet."},{"key":"62199_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.phrs.2015.08.024","volume":"102","author":"C Moon","year":"2015","unstructured":"Moon, C. et al. Drug-induced secretory diarrhea: a role for CFTR. Pharmacol. Res. 102, 107\u2013112 (2015).","journal-title":"Pharmacol. Res."},{"key":"62199_CR9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/j.1460-2075.1994.tb06355.x","volume":"13","author":"AC Chao","year":"1994","unstructured":"Chao, A. C. et al. Activation of intestinal CFTR Cl- channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase. EMBO J. 13, 1065\u20131072 (1994).","journal-title":"EMBO J."},{"key":"62199_CR10","doi-asserted-by":"publisher","first-page":"C708","DOI":"10.1152\/ajpcell.00544.2004","volume":"289","author":"F Golin-Bisello","year":"2005","unstructured":"Golin-Bisello, F., Bradbury, N. & Ameen, N. STa and cGMP stimulate CFTR translocation to the surface of villus enterocytes in rat jejunum and is regulated by protein kinase G. Am. J. Physiol. Cell Physiol. 289, C708\u2013C716 (2005).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"62199_CR11","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1073\/pnas.75.6.2669","volume":"75","author":"D Cassel","year":"1978","unstructured":"Cassel, D. & Pfeuffer, T. Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system. Proc. Natl. Acad. Sci. USA 75, 2669\u20132673 (1978).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62199_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1152\/advan.00035.2004","volume":"29","author":"BE Goodman","year":"2005","unstructured":"Goodman, B. E. & Percy, W. H. CFTR in cystic fibrosis and cholera: from membrane transport to clinical practice. Adv. Physiol. Educ. 29, 75\u201382 (2005).","journal-title":"Adv. Physiol. Educ."},{"key":"62199_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/ki.1996.304","volume":"50","author":"CJ Davidow","year":"1996","unstructured":"Davidow, C. J., Maser, R. L., Rome, L. A., Calvet, J. P. & Grantham, J. J. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int. 50, 208\u2013218 (1996).","journal-title":"Kidney Int."},{"key":"62199_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1681\/ASN.V1171179","volume":"11","author":"K Hanaoka","year":"2000","unstructured":"Hanaoka, K. & Guggino, W. B. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol. 11, 1179\u20131187 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"62199_CR15","doi-asserted-by":"publisher","first-page":"C389","DOI":"10.1152\/ajpcell.1996.270.1.C389","volume":"270","author":"K Hanaoka","year":"1996","unstructured":"Hanaoka, K., Devuyst, O., Schwiebert, E. M., Wilson, P. D. & Guggino, W. B. A role for CFTR in human autosomal dominant polycystic kidney disease. Am. J. Physiol. Cell Physiol. 270, C389\u2013C399 (1996).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"62199_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1152\/physrev.00007.2018","volume":"99","author":"L Csan\u00e1dy","year":"2019","unstructured":"Csan\u00e1dy, L., Vergani, P. & Gadsby, D. C. Structure, gating, and regulation of the CFTR anion channel. Physiol. Rev. 99, 707\u2013738 (2019).","journal-title":"Physiol. Rev."},{"key":"62199_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev-biophys-111622-091232","volume":"52","author":"A Alam","year":"2023","unstructured":"Alam, A. & Locher, K. P. Structure and mechanism of human ABC transporters. Annu. Rev. Biophys. 52, 275\u2013300 (2023).","journal-title":"Annu. Rev. Biophys."},{"key":"62199_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2017.02.024","volume":"169","author":"F Liu","year":"2017","unstructured":"Liu, F., Zhang, Z., Csan\u00e1dy, L., Gadsby, D. C. & Chen, J. Molecular structure of the human CFTR ion channel. Cell 169, 85\u201395.e8 (2017).","journal-title":"Cell"},{"key":"62199_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41586-023-05854-7","volume":"616","author":"J Levring","year":"2023","unstructured":"Levring, J. et al. CFTR function, pathology and pharmacology at single-molecule resolution. Nature 616, 606\u2013614 (2023).","journal-title":"Nature"},{"key":"62199_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1085\/jgp.20028673","volume":"121","author":"P Vergani","year":"2002","unstructured":"Vergani, P., Nairn, A. C. & Gadsby, D. C. On the mechanism of MgATP-dependent gating of CFTR Cl\u2212 channels. J. Gen. Physiol. 121, 17\u201336 (2002).","journal-title":"J. Gen. Physiol."},{"key":"62199_CR21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","volume":"379","author":"JC Davies","year":"2018","unstructured":"Davies, J. C. et al. VX-659\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1599\u20131611 (2018).","journal-title":"N. Engl. J. Med."},{"key":"62199_CR22","doi-asserted-by":"publisher","first-page":"9776","DOI":"10.1021\/jm5012808","volume":"57","author":"S Hadida","year":"2014","unstructured":"Hadida, S. et al. Discovery of N-(2,4-Di-Tert-Butyl-5-Hydroxyphenyl)-4-Oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator. J. Med. Chem. 57, 9776\u20139795 (2014).","journal-title":"J. Med. Chem."},{"key":"62199_CR23","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1073\/pnas.1215982110","volume":"110","author":"K-Y Jih","year":"2013","unstructured":"Jih, K.-Y. & Hwang, T.-C. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc. Natl. Acad. Sci. USA 110, 4404\u20134409 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62199_CR24","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating, D. et al. VX-445\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1612\u20131620 (2018).","journal-title":"N. Engl. J. Med."},{"key":"62199_CR25","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Van Goor","year":"2009","unstructured":"Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA 106, 18825\u201318830 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62199_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","volume":"185","author":"K Fiedorczuk","year":"2022","unstructured":"Fiedorczuk, K. & Chen, J. Mechanism of CFTR correction by type I folding correctors. Cell 185, 158\u2013168.e11 (2022).","journal-title":"Cell"},{"key":"62199_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1126\/science.ade2216","volume":"378","author":"K Fiedorczuk","year":"2022","unstructured":"Fiedorczuk, K. & Chen, J. Molecular structures reveal synergistic rescue of \u0394508 CFTR by trikafta modulators. Science 378, 284\u2013290 (2022).","journal-title":"Science"},{"key":"62199_CR28","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.aaw7611","volume":"364","author":"F Liu","year":"2019","unstructured":"Liu, F. et al. Structural identification of a hotspot on CFTR for potentiation. Science 364, 1184\u20131188 (2019).","journal-title":"Science"},{"key":"62199_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109703","volume":"73","author":"F Jouret","year":"2020","unstructured":"Jouret, F. & Devuyst, O. Targeting chloride transport in autosomal dominant polycystic kidney disease. Cell. Signal. 73, 109703 (2020).","journal-title":"Cell. Signal."},{"key":"62199_CR30","doi-asserted-by":"publisher","first-page":"C932","DOI":"10.1152\/ajpcell.00334.2021","volume":"321","author":"AS Verkman","year":"2021","unstructured":"Verkman, A. S. & Galietta, L. J. V. Chloride transport modulators as drug candidates. Am. J. Physiol. Cell Physiol. 321, C932\u2013C946 (2021).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"62199_CR31","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fphar.2019.00514","volume":"10","author":"G de Wilde","year":"2019","unstructured":"de Wilde, G. et al. Identification of GLPG\/ABBV-2737, a novel class of corrector, which exerts functional synergy with other CFTR modulators. Front. Pharmacol. 10, 514 (2019).","journal-title":"Front. Pharmacol."},{"key":"62199_CR32","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1021\/acs.jmedchem.3c01790","volume":"67","author":"M Pizzonero","year":"2024","unstructured":"Pizzonero, M. et al. Discovery of GLPG2737, a potent type 2 corrector of CFTR for the treatment of cystic fibrosis in combination with a potentiator and a type 1 co-corrector. J. Med. Chem. 67, 5216\u20135232 (2024).","journal-title":"J. Med. Chem."},{"key":"62199_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009969","volume":"15","author":"R Erdem","year":"2021","unstructured":"Erdem, R. et al. A phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model. PLoS Negl. Trop. Dis. 15, e0009969 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"62199_CR34","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1172\/JCI0216112","volume":"110","author":"T Ma","year":"2002","unstructured":"Ma, T. et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin\u2013induced intestinal fluid secretion. J. Clin. Invest. 110, 1651\u20131658 (2002).","journal-title":"J. Clin. Invest."},{"key":"62199_CR35","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.1021\/jm9009873","volume":"52","author":"L Tradtrantip","year":"2009","unstructured":"Tradtrantip, L., Sonawane, N. D., Namkung, W. & Verkman, A. S. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J. Med. Chem. 52, 6447\u20136455 (2009).","journal-title":"J. Med. Chem."},{"key":"62199_CR36","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1021\/jm200505e","volume":"54","author":"DS Snyder","year":"2011","unstructured":"Snyder, D. S., Tradtrantip, L., Yao, C., Kurth, M. J. & Verkman, A. S. Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J. Med. Chem. 54, 5468\u20135477 (2011).","journal-title":"J. Med. Chem."},{"key":"62199_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2316675121","volume":"121","author":"PG Young","year":"2024","unstructured":"Young, P. G., Levring, J., Fiedorczuk, K., Blanchard, S. C. & Chen, J. Structural basis for CFTR inhibition by CFTRinh-172. Proc. Natl. Acad. Sci. USA 121, e2316675121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62199_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50641-1","volume":"15","author":"X Gao","year":"2024","unstructured":"Gao, X. et al. Allosteric inhibition of CFTR gating by CFTRinh-172 binding in the pore. Nat. Commun. 15, 6668 (2024).","journal-title":"Nat. Commun."},{"key":"62199_CR39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1085\/jgp.201010518","volume":"136","author":"Z Kopeikin","year":"2010","unstructured":"Kopeikin, Z., Sohma, Y., Li, M. & Hwang, T.-C. On the mechanism of CFTR inhibition by a thiazolidinone derivative. J. Gen. Physiol. 136, 659\u2013671 (2010).","journal-title":"J. Gen. Physiol."},{"key":"62199_CR40","doi-asserted-by":"publisher","first-page":"8187","DOI":"10.1016\/j.bmc.2008.07.044","volume":"16","author":"ND Sonawane","year":"2008","unstructured":"Sonawane, N. D. & Verkman, A. S. Thiazolidinone CFTR inhibitors with improved water solubility identified by structure-activity analysis. Bioorg. Med. Chem. 16, 8187\u20138195 (2008).","journal-title":"Bioorg. Med. Chem."},{"key":"62199_CR41","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1111\/bph.12726","volume":"171","author":"N Melis","year":"2014","unstructured":"Melis, N. et al. Revisiting CFTR inhibition: a comparative study of CFTRinh -172 and GlyH-101 inhibitors. Br. J. Pharmacol. 171, 3716\u20133727 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"62199_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1124\/jpet.109.162032","volume":"333","author":"M Kelly","year":"2010","unstructured":"Kelly, M. et al. Cystic fibrosis transmembrane regulator inhibitors CFTR(Inh)-172 and GlyH-101 target mitochondrial functions, independently of chloride channel inhibition. J. Pharmacol. Exp. Ther. 333, 60\u201369 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"62199_CR43","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1096\/fj.201600891R","volume":"31","author":"O Cil","year":"2017","unstructured":"Cil, O. et al. Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins. FASEB J. 31, 751\u2013760 (2017).","journal-title":"FASEB J."},{"key":"62199_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/toxins14030225","volume":"14","author":"F Rivera-Ch\u00e1vez","year":"2022","unstructured":"Rivera-Ch\u00e1vez, F., Meader, B. T., Akosman, S., Koprivica, V. & Mekalanos, J. J. A Potent inhibitor of the cystic fibrosis transmembrane conductance regulator blocks disease and morbidity due to toxigenic vibrio cholerae. Toxins 14, 225 (2022).","journal-title":"Toxins"},{"key":"62199_CR45","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1124\/mol.115.098368","volume":"88","author":"Y Kim","year":"2015","unstructured":"Kim, Y. et al. Benzopyrimido-pyrrolo-oxazine-dione (R)-BPO-27 inhibits CFTR chloride channel gating by competition with ATP. Mol. Pharmacol. 88, 689\u2013696 (2015).","journal-title":"Mol. Pharmacol."},{"key":"62199_CR46","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1073\/pnas.0911061107","volume":"107","author":"L Csan\u00e1dy","year":"2010","unstructured":"Csan\u00e1dy, L., Vergani, P. & Gadsby, D. C. Strict Coupling between CFTR\u2019s catalytic cycle and gating of its Cl- ion pore revealed by distributions of open channel burst durations. Proc. Natl. Acad. Sci. USA 107, 1241\u20131246 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62199_CR47","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nature03313","volume":"433","author":"P Vergani","year":"2005","unstructured":"Vergani, P., Lockless, S. W., Nairn, A. C. & Gadsby, D. C. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 433, 876\u2013880 (2005).","journal-title":"Nature"},{"key":"62199_CR48","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1021\/ml400069k","volume":"4","author":"DS Snyder","year":"2013","unstructured":"Snyder, D. S. et al. Absolute configuration and biological properties of enantiomers of CFTR inhibitor BPO-27. ACS Med. Chem. Lett. 4, 456\u2013459 (2013).","journal-title":"ACS Med. Chem. Lett."},{"key":"62199_CR49","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1021\/ja01318a036","volume":"56","author":"H Lineweaver","year":"1934","unstructured":"Lineweaver, H. & Burk, D. The determination of enzyme dissociation constants. J. Am. Chem. Soc. 56, 658\u2013666 (1934).","journal-title":"J. Am. Chem. Soc."},{"key":"62199_CR50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2316673121","volume":"121","author":"J Levring","year":"2024","unstructured":"Levring, J. & Chen, J. Structural identification of a selectivity filter in CFTR. Proc. Natl. Acad. Sci. USA 121, e2316673121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62199_CR51","doi-asserted-by":"crossref","unstructured":"Simon, M. A., Iordanov, I., Sz\u00f6ll\u0151si, A. & Csan\u00e1dy, L. Estimating the true stability of the prehydrolytic outward-facing state in an ABC protein. eLife 12, e90736 (2023).","DOI":"10.7554\/eLife.90736"},{"key":"62199_CR52","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.cell.2017.06.041","volume":"170","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z., Liu, F. & Chen, J. Conformational changes of CFTR upon phosphorylation and ATP binding. Cell 170, 483\u2013491.e8 (2017).","journal-title":"Cell"},{"key":"62199_CR53","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.1073\/pnas.1815287115","volume":"115","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z., Liu, F. & Chen, J. Molecular structure of the ATP-bound, phosphorylated human CFTR. Proc. Natl Acad. Sci. 115, 12757\u201312762 (2018).","journal-title":"Proc. Natl Acad. Sci."},{"key":"62199_CR54","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"C Yung-Chi","year":"1973","unstructured":"Yung-Chi, C. & Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099\u20133108 (1973).","journal-title":"Biochem. Pharmacol."},{"key":"62199_CR55","doi-asserted-by":"crossref","unstructured":"McCullagh, M. et al. What Is Allosteric Regulation? Exploring the Exceptions That Prove the Rule! J. Biol. Chem. 300, 105672 (2024).","DOI":"10.1016\/j.jbc.2024.105672"},{"key":"62199_CR56","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/nchembio.1250","volume":"9","author":"S-R Tzeng","year":"2013","unstructured":"Tzeng, S.-R. & Kalodimos, C. G. Allosteric inhibition through suppression of transient conformational states. Nat. Chem. Biol. 9, 462\u2013465 (2013).","journal-title":"Nat. Chem. Biol."},{"key":"62199_CR57","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nchembio.2007.34","volume":"3","author":"L Luo","year":"2007","unstructured":"Luo, L. et al. ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat. Chem. Biol. 3, 722\u2013726 (2007).","journal-title":"Nat. Chem. Biol."},{"key":"62199_CR58","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.11.014","volume":"167","author":"Z Zhang","year":"2016","unstructured":"Zhang, Z. & Chen, J. Atomic structure of the cystic fibrosis transmembrane conductance regulator. Cell 167, 1586\u20131597.e9 (2016).","journal-title":"Cell"},{"key":"62199_CR59","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1038\/nprot.2014.173","volume":"9","author":"A Goehring","year":"2014","unstructured":"Goehring, A. et al. Screening and large-scale expression of membrane proteins in mammalian cells for structural studies. Nat. Protoc. 9, 2574\u20132585 (2014).","journal-title":"Nat. Protoc."},{"key":"62199_CR60","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"62199_CR61","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","volume":"192","author":"A Rohou","year":"2015","unstructured":"Rohou, A. & Grigorieff, N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216\u2013221 (2015).","journal-title":"J. Struct. Biol."},{"key":"62199_CR62","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jsb.2012.09.006","volume":"180","author":"SHW Scheres","year":"2012","unstructured":"Scheres, S. H. W. RELION: implementation of a bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519\u2013530 (2012).","journal-title":"J. Struct. Biol."},{"key":"62199_CR63","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"62199_CR64","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"62199_CR65","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"62199_CR66","first-page":"790","volume":"93","author":"BF Scharschmidt","year":"1979","unstructured":"Scharschmidt, B. F., Keeffe, E. B., Blankenship, N. M. & Ockner, R. K. Validation of a recording spectrophotometric method for measurement of membrane-associated Mg- and NaK-ATPase activity. J. Lab. Clin. Med. 93, 790\u2013799 (1979).","journal-title":"J. Lab. Clin. Med."},{"key":"62199_CR67","doi-asserted-by":"crossref","unstructured":"Young, P. G., Fiedorczuk, K. & Chen, J. Complex of the phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with (R)-BPO-27 and ATP\/Mg. https:\/\/www.ebi.ac.uk\/pdbe\/entry\/emdb\/EMD-48717 (2025).","DOI":"10.2210\/pdb9mxl\/pdb"},{"key":"62199_CR68","doi-asserted-by":"publisher","unstructured":"Young, P. G., Fiedorczuk, K. & Chen, J. Complex of the phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with (R)-BPO-27 and ATP\/Mg. https:\/\/doi.org\/10.2210\/9MXL\/pdb (2025).","DOI":"10.2210\/9MXL\/pdb"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62199-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62199-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62199-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:10:48Z","timestamp":1757337048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62199-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62199"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62199-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7059"}}